KINTOR PHARMACEUTICAL LIMITED Funds and ETFs Kintor Pharmaceutical Limited
Equities
9939
KYG5273B1077
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.96 HKD | +2.13% |
|
+10.34% | -41.10% |
ETFs positioned on Kintor Pharmaceutical Limited
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.58% | 4 M€ | -27.92% | ||
| 0.02% | 2 M€ | -.--% | ||
| 0.01% | 7 M€ | -.--% | - | |
| 0.00% | 117 M€ | +1.11% | - | |
| 0.00% | 4 M€ | -4.41% | - | |
| 0.00% | 34 M€ | +2.14% | - |
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China. The Company is focused on the research and development of drugs for cancers and other androgen receptor (AR) related diseases. Its primary drug candidate is Proxalutamide which is in phase III clinical trials in China for metastatic castration-resistant prostate cancer (mCRPC). The Company are also developing other drug candidates, including a phase II small molecule drug candidate Pyrilutamide, a phase II monoclonal antibody drug candidate ALK-1, a phase I mTOR inhibitor drug candidate Detorsertib and an inhibitor of the hedgehog signal translation pathway GT1708F.
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.8886
CNY
Average target price
13.21
CNY
Spread / Average Target
+1,386.53%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -41.10% | 54.88M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 9939 Stock
- Funds and ETFs Kintor Pharmaceutical Limited
